• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypercholesterolemia-Pipeline Review H1 2017

    Hypercholesterolemia-Pipeline Review H1 2017

    • Report Code ID: RW0001834323
    • Category Pharmaceuticals
    • No. of Pages 197
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Hypercholesterolemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H1 2017, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

    Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 14, 3, 1, 1, 20, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

    Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 5
    Hypercholesterolemia - Overview 6
    Hypercholesterolemia - Therapeutics Development 7
    Hypercholesterolemia - Therapeutics Assessment 18
    Hypercholesterolemia - Companies Involved in Therapeutics Development 28
    Hypercholesterolemia - Drug Profiles 47
    Hypercholesterolemia - Dormant Projects 170
    Hypercholesterolemia - Discontinued Products 174
    Hypercholesterolemia - Product Development Milestones 175
    Appendix 189

    List of Tables

    Number of Products under Development for Hypercholesterolemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hypercholesterolemia - Pipeline by 3SBio Inc, H1 2017
    Hypercholesterolemia - Pipeline by AFFiRiS AG, H1 2017
    Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H1 2017
    Hypercholesterolemia - Pipeline by Alvogen Korea Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by ARMO Biosciences Inc, H1 2017
    Hypercholesterolemia - Pipeline by AstraZeneca Plc, H1 2017
    Hypercholesterolemia - Pipeline by BioLingus AG, H1 2017
    Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
    Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H1 2017
    Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
    Hypercholesterolemia - Pipeline by Dybly AG, H1 2017
    Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H1 2017
    Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H1 2017
    Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H1 2017
    Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H1 2017
    Hypercholesterolemia - Pipeline by Johnson & Johnson, H1 2017
    Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H1 2017
    Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H1 2017
    Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H1 2017
    Hypercholesterolemia - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Merck & Co Inc, H1 2017
    Hypercholesterolemia - Pipeline by Pfizer Inc, H1 2017
    Hypercholesterolemia - Pipeline by Planet Biotechnology Inc, H1 2017
    Hypercholesterolemia - Pipeline by Progenra Inc, H1 2017
    Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Hypercholesterolemia - Pipeline by RegenxBio Inc, H1 2017
    Hypercholesterolemia - Pipeline by Serometrix LLC, H1 2017
    Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
    Hypercholesterolemia - Pipeline by Solvotrin Therapeutics Ltd, H1 2017
    Hypercholesterolemia - Pipeline by The Medicines Company, H1 2017
    Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H1 2017
    Hypercholesterolemia - Dormant Projects, H1 2017
    Hypercholesterolemia - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Hypercholesterolemia - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Hypercholesterolemia - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Hypercholesterolemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hypercholesterolemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    3SBio Inc
    AFFiRiS AG
    Akcea Therapeutics Inc
    Alvogen Korea Co Ltd
    ARMO Biosciences Inc
    AstraZeneca Plc
    BioLingus AG
    Catabasis Pharmaceuticals Inc
    Chong Kun Dang Pharmaceutical Corp
    CymaBay Therapeutics Inc
    Daewon Pharm Co Ltd
    Daewoong Co Ltd
    Dicerna Pharmaceuticals Inc
    Dybly AG
    Esperion Therapeutics Inc
    Gemphire Therapeutics Inc
    Golden Biotechnology Corp
    Hanmi Pharmaceuticals Co Ltd
    Immune Response BioPharma Inc
    Johnson & Johnson
    Kadmon Corp LLC
    Kyorin Pharmaceutical Co Ltd
    Leading BioSciences Inc
    LipimetiX Development Inc
    Lotus Pharmaceutical Co Ltd
    Medlab Clinical Ltd
    Merck & Co Inc
    Pfizer Inc
    Planet Biotechnology Inc
    Progenra Inc
    Regeneron Pharmaceuticals Inc
    RegenxBio Inc
    Serometrix LLC
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    Solvotrin Therapeutics Ltd
    The Medicines Company
    Viking Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hypercholesterolemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypercholesterolemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypercholesterolemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments